摘要:
A multimer peptide from a snake venom has an activity to inhibit binding between von Willebrand factor and platelets. The multimer peptide is used to obtain a single strand peptide which does not substantially cause decrease in platelets at a minimum dose for exhibiting the activity in vivo. The single strand peptide is obtained by allowing the multimer peptide to exist together with a protein-denaturing agent, and glutathione and/or cysteine, and thereby disconnecting disulfide bonds between peptide chains for constituting the multimer peptide while substantially preserving disulfide bonds within the peptide chains. Alternatively, the single strand peptide, a mutant thereof, or a part thereof is produced by genetic engineering techniques by using genes coding for them.
摘要:
A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.
摘要:
A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.
摘要:
A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet aggregation), and SIPA (shear stress-induced platelet aggregation) of human platelet, and which does not express bleeding action in an medicinally effective dose to exhibit antithrombotic action, is used as an active ingredient of an antithrombotic agent.
摘要:
A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bottrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.
摘要:
A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bottrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.
摘要:
A method for conveniently detecting binding between the von Willebrand factor and glycoprotein Ib and a means to be used therein. The von Willebrand factor fixed in a reactor immobilized in a reaction vessel in the presence of bottrocetin is bound to a chimeric protein constructed by fusing the carboxyl terminal of a partial protein containing the von Willebrand factor-binding site of glycoprotein Ib with the amino terminal of the Fc region of an immunoglobulin molecule. Then the Fc region of the above immunoglobulin molecule is detected to thereby detect the binding between the von Willebrand factor and the glycoprotein Ib or inhibition of this binding.
摘要:
It is provided a method for producing a subunit peptide originating from an oligomeric protein having disulfide bonds within a subunit and between subunits. The method comprises producing a subunit originating from an oligomeric protein having disulfide bonds within a subunit and between subunits by the following steps: (a) a step of refolding the subunit by denaturing the oligomeric protein or its subunit in a solution with a protein-denaturing agent and removing the denaturing agent from the solution in the presence of polyoxyalkyl polyether having a functional group that reacts with a thiol group; and (b) a step of isolating the subunit bonded to the polyoxyalkyl polyether from the solution.
摘要:
A method for producing a protein having an antithrombotic activity, which comprises replacing, in a protein that has an amino acid sequence having a homology of not less than 30% to the amino acid sequence of SEQ ID NO: 1 and forms a higher order structure composed of a first β strand (β1), a first a helix (α1), a second α helix (α2), a second β strand (β2), a loop, a third β strand (β3), a fourth β strand (β4) and a fifth β strand (β5) in this order from the amino terminus, at least one amino acid residue in a region from α2 to β2 and/or a region from β3 to β4 so that electric charge of the amino acid residue is changed towards positive direction.
摘要翻译:一种具有抗血栓形成活性的蛋白质的制造方法,其特征在于,具有与SEQ ID NO:1的氨基酸序列具有不小于30%的同源性的氨基酸序列的蛋白质,并形成高级结构 由第一个β链(beta1),第一个螺旋(alpha1),第二个α螺旋(alpha2),第二个β链(β2),一个环,第三个β链(β3),第四个β链 β4)和第五个β链(β5),从氨基末端起始,α2至β2区域和/或β3至β4区域中的至少一个氨基酸残基,使得氨基酸残基的电荷为 转向正向。
摘要:
A method for producing a protein having an antithrombotic activity, which comprises replacing, in a protein that has an amino acid sequence having a homology of not less than 30% to the amino acid sequence of SEQ ID NO: 1 and forms a higher order structure composed of a first &bgr; strand (&bgr;1), a first &agr; helix (&agr;1), a second &agr; helix (&agr;2), a second &bgr; strand (&bgr;2), a loop, a third &bgr; strand (&bgr;3), a fourth &bgr; strand (&bgr;4) and a fifth &bgr; strand (&bgr;5) in this order from the amino terminus, at least one amino acid residue in a region from &agr;2 to &bgr;2 and/or a region from &bgr;3 to &bgr;4 so that electric charge of the amino acid residue is changed towards positive direction.
摘要翻译:一种具有抗血栓形成活性的蛋白质的制造方法,其特征在于,具有与SEQ ID NO:1的氨基酸序列具有不小于30%的同源性的氨基酸序列的蛋白质,并形成高级结构 由第一β链(β1),第一α螺旋(alpha1),第二α螺旋(α2),第二β链(β2),环,第三β链(β3),第四条β链 β4)和第五个β链(β5),从氨基末端起始,α2至β2区域和/或β3至β4区域中的至少一个氨基酸残基,使得氨基酸残基的电荷为 转向正向。